Water Leaders to Accelerate Action Towards UN Sustainable Development Goals at IWA World Water Congress 2022
12.9.2022 12:00:00 EEST | Business Wire | Press release
There are 2.3 billion people who now live in water-stressed countries and 18 million people risk being displaced by floods every year1. Against this backdrop, global water technology company Xylem (NYSE: XYL), will join water sector leaders at the IWA World Water Congress & Exhibition, to explore solutions to build water security. Xylem executives will share perspectives on actions to increase communities’ resilience to water scarcity, and strategies to accelerate the decarbonization of water networks.
The congress takes place in Copenhagen, Denmark, 11-15 September 2022. On Wednesday, September 14, Dave Flinton, Xylem’s Chief Innovation, Technology and Product Management Officer, will discuss the business models and multidisciplinary approaches needed for successful innovation in resource recovery. Learning to Dance in the Rain — How to Thrive in an Era of Climate Change, will explore actions taken to date and future trends.
Commenting on the congress, Dave Flinton said, “Technology can make communities more resilient in the face of severe weather. Through innovation and collaboration, we can modernize water systems so that communities have affordable, accessible water, and are buffered from shocks like droughts and floods.”
On Monday, September 12, Austin Alexander, Vice President, Sustainability and Social Impact at Xylem, will take part in a keynote plenary discussion – Practical Perspectives in Building Resilience into Urban Water Management. During the session, she will share insights on building urban resiliency in the face of climate change, the solutions that are available, and the importance of maintaining momentum on the UN SDGs. As water infrastructure is a contributor to greenhouse gas (GHG) emissions, Alexander will also touch on the use of technology to meaningfully reduce emissions and help transform the future of water management.
On Wednesday, September 14, Xylem’s Global Procurement Sustainability Manager, Andrea Montuori will participate in a keynote plenary session on Uniting Youth for Water. This session will examine the role of youth within the water sector, with a special focus on the UN 2023 Water Conference, taking place in March next year.
Xylem will also hold two business forums at the congress:
- On Tuesday, September 13, Joost Aloserij, Director of Business Development, Central & North Europe at Xylem, will lead a forum on Let's Redefine what's Possible for Water. Drawing on Xylem Vue, Xylem’s digital solutions platform that combines smart, connected technologies with intelligent systems and services. This session will focus on how utilities can embrace digital innovation to improve performance, reduce costs, and better serve their communities.
- On Wednesday, September 14, Alexis De Kerchove, Senior Director, Marketing and Business Development, Europe Commercial Team, will lead a forum on Road to Net Zero, alongside Austin Alexander. This session will explore the importance of decarbonization for water and wastewater utilities.
Xylem is also the proud sponsor of the IWA Climate Smart Utilities Recognition Program which aims to inspire utilities and all their stakeholders to become Climate Smart and embrace climate resilience under three key pillars for action – adaptation, mitigation, and leadership. Following a robust review, forty-two Climate Smart utilities will be honored at the IWA World Water Congress & Exhibition closing ceremony on Thursday, September 15.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management and helping communities in more than 150 countries become water secure. Join us at www.xylem.com.
______________________
1
https://www.internal-displacement.org/global-report/grid2019/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005444/en/
Contact information
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom